Clinical and Translational Allergy最新文献

{"title":"Quality of life in type 2 and non-type 2 endotypes in chronic rhinosinusitis with nasal polyps: A prospective trial","authors":"Stijn Bogaert,&nbsp;Elisabeth Rheindorf,&nbsp;Stefan Dazert,&nbsp;Stefan Volkenstein,&nbsp;Lisa Knipps,&nbsp;Jonas Jae-Hyun Park,&nbsp;Oliver Pfaar","doi":"10.1002/clt2.70070","DOIUrl":"https://doi.org/10.1002/clt2.70070","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>In current clinical practice, primary diffuse chronic rhinosinusitis with nasal polyps (CRSwNP) is classified into two endotypes: type 2 and non-type 2. Previous studies on sinonasal health-related quality of life (HRQoL) in CRS have primarily focused on differences between phenotypes. This study aimed to compare HRQoL between the two endotypes in patients with CRSwNP.</p>\u0000 \u0000 <p>The type 2 endotype had a higher median nasal polyp score (NPS) than non-types (4 and 2, respectively), but this difference did not reach significance. Loss of smell was associated with NPS, and facial pain/pressure was inversely correlated with age. Age was significantly associated with loss of smell, but only in non-type 2 CRSwNP.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This was a prospective, monocentric study conducted between 2018 and 2023 on CRSwNP patients referred for surgery. Health-related quality of life was assessed using the German standardized SNOT-20 questionnaire. Type 2 was defined according to the updated EPOS/EUFOREA 2023 criteria.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 122 patients with CRSwNP were included, 113 (92.6%) of whom were classified as type 2. Type 2 was associated with a significantly worse SNOT-20 German Adapted Version score. Two of the four cardinal symptoms of CRS—loss of smell and rhinorrhea—were significantly more severe and prevalent in the type 2 endotype, with loss of smell being very specific. The most prevalent symptom in both endotypes was nasal obstruction, with no difference between both endotypes.</p>\u0000 \u0000 <p>The type 2 endotype had a higher median nasal polyp score (NPS) than non-types (4 and 2, respectively), but this difference did not reach significance. Loss of smell was associated with NPS, and facial pain/pressure was inversely correlated with age. Age was significantly associated with loss of smell, but only in non-type 2 CRSwNP.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Type 2 CRSwNP has a more severe impact on HRQoL compared with non-type 2 CRSwNP. Hyposmia, rhinorrhea, and potentially NPS may offer endotypic and pathophysiological insights.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"15 6","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70070","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144185876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of asthma in individuals with eosinophilic esophagitis: Population-based cohort study with sibling analyses","authors":"Niki Mitselou,&nbsp;Amiko Uchida,&nbsp;Bjorn Roelstraete,&nbsp;Erik Melén,&nbsp;John J. Garber,&nbsp;Jonas F. Ludvigsson","doi":"10.1002/clt2.70068","DOIUrl":"https://doi.org/10.1002/clt2.70068","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>There are limited data on the relationship between eosinophilic esophagitis (EoE) and asthma. We aimed to assess the risk of asthma in EoE patients compared with matched controls and siblings.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Through the ESPRESSO study, a Swedish nationwide population-based histopathology cohort, we identified EoE patients diagnosed between 1989 and 2017 (<i>n</i> = 1146) and up to 5 age- and sex-matched controls (<i>n</i> = 5022). Cox regression generated hazard ratios (HRs) for developing asthma. We compared EoE patients with sibling controls.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The median age at EoE diagnosis was 42 years. During a median follow-up of 3.8 years, 140 EoE patients (28.1/1000 person-years) and 174 controls (7.2/1000 person-years) developed asthma (HR = 3.96; 95% confidence interval [CI] = 3.16–4.96, <i>p</i> &lt; 0.001). An increased risk of asthma was seen in the first 10 years after EoE diagnosis but not thereafter. EoE patients diagnosed in childhood or young adulthood were at a particularly high risk of asthma (HR = 4.74; 95% CI = 2.93–7.67, <i>p</i> &lt; 0.001 and HR = 5.84; 95% CI = 3.68–9.29, <i>p</i> &lt; 0.001, respectively). Compared with their non-EoE siblings, EoE patients were at a 5-fold increased risk of asthma (HR = 4.97; 95% CI = 3.13–7.92, <i>p</i> &lt; 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>EoE patients are at an increased risk of asthma compared with the general population, which is unlikely to be entirely explained through unmeasured intrafamilial factors given that the positive association remained in sibling analyses. Physicians caring for EoE should have a high awareness of concomitant asthma.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"15 6","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70068","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144185875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between telomere length and atopic dermatitis among school-age children","authors":"Hsin-Yi Huang,&nbsp;Kun-Hua Sheen,&nbsp;Chi-Yen Hung,&nbsp;Ju Chang-Chien,&nbsp;Shih-Ling Wang,&nbsp;Chia-Hua Ho,&nbsp;Hui-Ju Tsai,&nbsp;Tsung-Chieh Yao","doi":"10.1002/clt2.70066","DOIUrl":"https://doi.org/10.1002/clt2.70066","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Atopic dermatitis is a common chronic skin disease in children. Whether telomere length is associated with atopic dermatitis remains unclear. This population-based case-control study aimed to investigate the association between telomere length and atopic dermatitis in school-age children.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this cross-sectional analysis, we included 1084 singleton term-born children (608 males; mean age 6.4 years) from the Longitudinal Investigation of Global Health in Taiwanese Schoolchildren cohort. Telomere length was measured using quantitative real-time polymerase chain reaction, log-transformed and was analyzed in quartiles. The main outcome was atopic dermatitis defined as having physician-diagnosed atopic dermatitis and the presence of atopic dermatitis in the last 12 months. Regression analyses were used to assess the relationship between telomere length and atopic dermatitis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Telomere length was significantly inversely associated with childhood atopic dermatitis after adjusting for child's age, sex, overweight or obesity, birth season, childhood allergic diseases, environmental tobacco smoke, parental history of allergic diseases, parental educational level, and breastfeeding status (<i>p</i>__trend = 0.01). Specifically, when telomere length was classified into quartiles, children in the shortest (fourth) telomere length quartile had a 1.88-fold higher probability of atopic dermatitis compared to those in the longest (first) quartile (95% confidence interval: 1.13–3.14). Stratified analyses showed that the associations were stronger in males and non-breastfed children, with no significant associations observed in females or breastfed children.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study provides new evidence suggesting an association between shorter telomere length and atopic dermatitis in school-age children.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"15 6","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70066","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144171800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"All change, 2025","authors":"Clive Grattan,&nbsp;Jean Bousquet","doi":"10.1002/clt2.70063","DOIUrl":"https://doi.org/10.1002/clt2.70063","url":null,"abstract":"<p>Professor Oliver Pfaar took over as Editor-in-Chief of Clinical and Translational Allergy (CTA) in April 2025 with Professor Maria Escribese as deputy editor. The journal was founded by Professor Jan Lötvall in 2011 when open access publication of scientific papers on the web to a worldwide readership without restriction to subscription journals was an innovation. Dr Clive Grattan was appointed in 2012 to lead the development of this new initiative of the European Academy of Allergy and Clinical Immunology (EAACI). Professor Jean Bousquet was appointed Co-editor in Chief in 2016.</p><p>The primary aim of CTA is to communicate applied science and clinical research in the field of allergy to daily clinical practice in the English language. The most frequently published article types are original articles, reviews, position articles and letters to the editor. The impact factor has increased from 3.239 at launch in 2016 to 4.6 in 2023. Publication impact is also reflected in altmetrics scores and social media dissemination. The number of manuscript submissions has increased steadily, with a year-on-year increase in 2023 of 8.8%. The acceptance rate of 34.9% in 2023 was comparable to other Allergy and Clinical Immunology journals. Submitted and published manuscripts come from across the globe. CTA migrated from BioMed Central to Wiley in 2021 to align with its two sister journals in the EAACI portfolio; Allergy and Paediatric Allergy and Immunology. Having a single publisher has facilitated the transfer of submitted manuscripts between the EAACI journals via Editor Driven Referral. This represented 29% of total submissions to CTA in 2023. The number of accesses and downloads has increased year-on-year.</p><p>The cost of open access publishing falls to the author or institution rather than the journal owner and its publisher but, in return, the copyright belongs to the copyright holder who is free to read, share and download their work immediately on publication. Different schemes are available to support the cost, including contracts between publishers, funders and research institutions. Waivers or discounts on the article processing charges (APC) are available through Wiley for low-income countries. EAACI offers discounted APCs for members.</p><p>Highly cited early publications in CTA including Diagnostic tools in Rhinology EAACI position paper (2011), mechanisms of allergen-specific immunotherapy (2012), diagnosis and management of non-IgE mediated cow's milk allergy in infancy – a UK primary care practical guide (2013), fungal allergy in asthma – state of the art and research needs (2014) and the role of IL-33 and mast cells in allergy and inflammation (2015) showpiece the breadth and quality of its content. Emerging technologies for predictive medicine in rhinitis and asthma across the life cycle have been an important innovation in generating large amounts of real world data in rhinitis, rhinosinusitis and asthma by engaging patients and their","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"15 5","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70063","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144118026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"20 years of the socioeconomic impact of atopic dermatitis and alopecia areata from around the globe","authors":"Katarina Stevanovic,&nbsp;Manuel Pereira,&nbsp;Ophélie Nguyen,&nbsp;Ingrid van Hofman,&nbsp;Cathrin Meesch,&nbsp;Torsten Zuberbier","doi":"10.1002/clt2.70061","DOIUrl":"https://doi.org/10.1002/clt2.70061","url":null,"abstract":"<p>Atopic dermatitis (AD) and alopecia areata (AA) represent chronic inflammatory diseases characterized by heterogeneous immune-mediated mechanisms, including subtypes that may interconnect the two diseases, as well as other comorbidities. AD is globally recognized as the most common inflammatory skin disease and AA is an autoimmune disease, causing non-scarring hair loss. In both diseases the quality of life (QoL) is decreased, out-of-pocket expenses on alternative therapies and camouflage endeavours is high, increased productivity loss/absenteeism at work or school, and high healthcare costs are significant. These diseases are not life threatening but result in a substantial socioeconomic impact, which so far has been difficult to quantify on the global scale. This qualitative review that includes literature published between 2004 and 2024 evaluates the current alignment between available healthcare resources and the comprehensive needs of these patients. Currently available data indicates that the socioeconomic impact of AD and AA is evidently high, meanwhile there is data lacking from most countries in Africa, Scandinavia and East Europe, the Middle East, South Asia, and parts of Latin America. Global studies with standardized methodology are necessary to assess the socio-economic impact of these conditions.</p>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"15 5","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70061","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144100566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The diagnosis of lipid transfer protein allergy—Discriminating between sensitisation and allergy","authors":"B. Olivieri,&nbsp;G. Scadding,&nbsp;I. J. Skypala","doi":"10.1002/clt2.70065","DOIUrl":"https://doi.org/10.1002/clt2.70065","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Sensitisation to Lipid Transfer Proteins (LTP), usually ascertained by undertaking a test to the peach LTP allergen Pru p 3, is common but does not always indicate LTP allergy. Improving the diagnostic process would ensure the correct diagnosis and management of this complex condition.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To determine the diagnostic value of Pru p 3 and other LTP component allergens in UK adults.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A retrospective review was undertaken of adults referred to the Allergy Unit at the Royal Brompton &amp; Harefield Hospitals (RBHT) London (UK), between 2012 and 2022 who were sensitised to Pru p 3. Those with a final diagnosis of LTP allergy were compared to those sensitized to Pru p 3 but not diagnosed with LTP allergy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of 285 patients with a positive Pru p 3, 157 (55%) were diagnosed with LTP allergy. LTP allergic patients were more likely to have a higher level of Pru p 3, and a lower level of total IgE. The ratio of Pru p 3:total IgE was the most accurate diagnostic marker of LTP allergy, with a receiver operating characteristics AUC of 0.880. A diagnosis of LTP allergy was also significantly associated with sensitisation to the LTP in peanut (Ara h 9, <i>p</i> &lt; 0.001), and hazelnut (Cor a 8, <i>p</i> &lt; 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Sensitisation to Pru p 3 may not always indicate an LTP allergy. Our data suggests that the Pru p 3:total IgE ratio, and sensitisation to Ara h 9 and Cor a 8 can support the diagnosis of LTP allergy in individuals sensitised to Pru p 3.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"15 5","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70065","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144108837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Requalification of patients with severe asthma for biological therapy—Practical ‘ReQuaBi’ rate decision scheme based on the analytical model","authors":"Alicja Majos,&nbsp;Anna Ben Drissi,&nbsp;Maciej Kupczyk,&nbsp;Michał Panek","doi":"10.1002/clt2.70059","DOIUrl":"https://doi.org/10.1002/clt2.70059","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Patients with severe asthma experience decreased quality of life due to fixed airway obstruction, hospitalisations and potential fatalities. However, to date, the requalification of severe asthma patients eligible for biological therapy in daily clinical practice remains unstudied.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The aim of the study was to prepare a universal decision-making algorithm for requalifying patients for biological therapy based on available clinical data obtained from a leading reference centre in Poland.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>All severe asthma patients treated with biologics since 2013 at the Internal Medicine, Asthma and Allergy Department (Medical University of Lodz, Poland), were analysed. The analysis included demographic (age, sex), pre-treatment (reported at qualification: oral glucocorticosteroids use, total IgE serum level, peripheral blood eosinophilia, co-morbidities: atopic dermatitis, chronic allergic rhinitis or sinusitis) and treatment-related data (treatment time, current treatment status, reason for early termination of therapy, year of discontinuation, rediagnostics, requalification).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Rediagnostics were performed in only 4.76% of all requalifications. The following additional data were used to requalify patients: blood eosinophilia (<i>n</i> = 63; 100.00% of requalifications), atopic comorbidities (<i>n</i> = 30; 47.62%) and total IgE serum level (<i>n</i> = 8; 12.70%). Kaplan–Meier curve analysis of all source data revealed the longevity of maintenance as follows: the highest for mepolizumab, then omalizumab, benralizumab, dupilumab and tezepelumab (<i>p</i> = 0.016). Based on the results, requalification model ‘ReQuaBi’, was constructed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The most important criteria for selecting a biological agent in requalification are peripheral blood eosinophilia, followed by comorbidities and IgE levels. In most cases, extensive additional re-diagnosis may not be necessary.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"15 5","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70059","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143926157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"T cell immunophenotypes and IgE responses in patients with moderate-to-severe atopic dermatitis receiving dupilumab","authors":"Davender Redhu,&nbsp;Wojciech Francuzik,&nbsp;Philipp Globig,&nbsp;Margitta Worm","doi":"10.1002/clt2.70062","DOIUrl":"https://doi.org/10.1002/clt2.70062","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Targeting the interleukin-4 receptor alpha (IL-4Rα) subunit has proven clinical efficacy in atopic dermatitis (AD).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study assessed the peripheral phenotype and function of T-cells, but also levels of total and sIgE and its receptors in AD patients receiving dupilumab.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>AD patients were clinically assessed (<i>n</i> = 75) and peripheral blood samples were taken (<i>n</i> = 25). Multiparametric flow cytometry was performed to characterize T-cell subsets (before treatment and 6 months later). Total and specific IgE were measured by ImmunoCap, soluble CD23 and FcεR1 in serum by ELISA, and eosinophils by differential blood analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>SCORing Atopic Dermatitis scores and body surface area involvement decreased upon treatment after 6 months of treatment to 67% and 77% from baseline. At the T cell level, we observed a 0.55-fold reduction of Th2-cells and a mean 27% increase in regulatory T-cells from baseline, accompanied by shifts towards Th1 and Th17 phenotypes. Furthermore, circulating CD4⁺CXCR5⁺TFH17 and CD4⁺CXCR5⁺TFH17.1 positive cells (mean 40% and 42%) and T-cell-specific IL-2 (+0.96-fold) and IL-10 (+1.96-fold) secretion increased, whereas IL-4 (mean −55%) and IL-17A (mean −27%) were reduced. Eosinophil counts (mean −22%), total IgE (mean −47%) and House Dust Mite sIgE (mean −40%) decreased, whereas CD23 and FcεR1 remained unchanged.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The T-cell and cytokine profiles during anti-IL4-Ra treatment suggest that targeting this pathway promotes a systemic shift of the T-cell compartment by reducing the T helper type 2 and complementary IgE responses. The sustainability of these disease-modifying effects requires further investigation.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"15 5","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70062","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143925777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-genetic factors associated with ACE-inhibitor and angiotensin receptor blocker-induced angioedema","authors":"Diana Dubrall,&nbsp;Nora L. Branding,&nbsp;Carina M. Mathey,&nbsp;Anna M. Weber,&nbsp;Michael Steffens,&nbsp;Maike Below,&nbsp;Matthias Schmid,&nbsp;Bettina Wedi,&nbsp;Dorothea Wieczorek,&nbsp;Philipp M. Amann,&nbsp;Harald Löffler,&nbsp;Lukas Koch,&nbsp;Clemens Schöffl,&nbsp;Heinrich Dickel,&nbsp;Nomun Ganjuur,&nbsp;Thorsten Hornung,&nbsp;Timo Buhl,&nbsp;Emel Aygören-Pürsün,&nbsp;Gerda Wurpts,&nbsp;Jens Greve,&nbsp;Markus M. Nöthen,&nbsp;Andreas J. Forstner,&nbsp;Bernhardt Sachs","doi":"10.1002/clt2.70058","DOIUrl":"https://doi.org/10.1002/clt2.70058","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Angioedema (AE) rarely occurs as a potentially life-threatening adverse drug reaction (ADR) to angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB). The aim of the present study was to investigate non-genetic association factors with ACEi-/ARB-induced angioedema in the European ADR database EudraVigilance and the database of the vARIANCE study.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The cohort of the vARIANCE study comprised 114 patients who suffered from ACEi- or ARB-induced angioedema. In addition, 171 angioedema reports and 4650 reports on other ADRs of ACEi/ARB were identified in the ADR database EudraVigilance with the latter serving as a reference group. Odds ratios were calculated and a logistic regression analysis was performed using angioedema versus reference reports.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Increased age, smoking, allergies and a history of previous angioedema were identified as associated factors for ACEi-/ARB-induced angioedema. In most patients, the swelling affected the face, lips and tongue. In the vARIANCE study, about 70% of angioedema occurred after 1 year of treatment. For one in two patients in the vARIANCE study (84.2% with ACEi treatment) and one in three patients from the EudraVigilance reports (59.6% with ARB treatment), the angioedema resulted in hospitalization.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>We found small to moderate associations with certain individual patient-related factors in this pharmaco-epidemiological study. As a future perspective, combining non-genetic association factors with corresponding genetic data might provide an option to compose stronger and individual risk scores.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"15 5","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70058","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143919330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biological and target synthetic treatments for chronic spontaneous urticaria: A systematic review and network meta-analysis","authors":"Zuotao Zhao,&nbsp;Yaqi Zheng,&nbsp;Xiaoting Song,&nbsp;Chengyue Peng,&nbsp;Shuanglu Liao,&nbsp;Peixin Zhang,&nbsp;Yen Tan,&nbsp;Xiaojie Huang,&nbsp;Litao Zhang","doi":"10.1002/clt2.70052","DOIUrl":"https://doi.org/10.1002/clt2.70052","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Most biological and synthetic target-specific drugs for antihistamine-refractory chronic spontaneous urticaria (CSU) have not been compared head-to-head. This systematic review and network meta-analysis evaluated their relative efficacy and safety.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Searches were conducted on PubMed, Embase, Web of Science and Cochrane library databases to March 25, 2024 for randomized trials. A random-effects model was used to calculate the network estimates reported as mean differences (MD) and odds ratios (OR) with corresponding 95% CIs. Main outcomes included the weekly urticaria activity score (UAS7), adverse events (AEs) and serious adverse events (SAEs).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>23 randomized clinical trials with 6933 participants that compared 26 different interventions or dosages and placebos were included. Omalizumab 300 mg [MD −10.07, 95% CI (−11.35; −8.82)] continues to demonstrate superior efficacy compared with placebo. Remibrutinib, at doses of 35 mg once daily [MD −7.80, 95% CI (−12.76; −2.51)], 25 mg twice daily [MD −7.69, 95% CI (−9.85; −5.76)], and 10 mg twice daily [MD −7.61, 95% CI (−12.59; −2.47)], had the best overall performance for efficacy and safety. Dupilumab, fenebrutinib, and rilzabrutinib also showed greater efficacy than placebo. The results were similar for the proportion of patients who achieved UAS7 ≤ 6 or UAS7 = 0. No significant differences were found among all treatment comparisons for AEs and SAEs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The findings of this study indicate that the biological agent omalizumab 300 mg and the oral small molecule remibrutinib at doses of 35 mg, 25 mg, or 10 mg are recommended for patients with antihistamine-refractory CSU.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>PROSPERO: CRD42024516289</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"15 5","pages":""},"PeriodicalIF":4.6,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70052","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143909212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}